实用老年医学

实用老年医学 ›› 2021, Vol. 35 ›› Issue (12): 1232-1235.doi: 10.3969/j.issn.1003-9198.2021.12.006

• 临床研究 • 上一篇    下一篇

累及野放疗联合替吉奥治疗老年食管癌的Ⅱ期临床研究

张治, 周国仁, 叶劲军, 顾大勇, 李慧, 陈薇, 方瑛, 陈诚, 钱普东, 陶华, 朱向帜, 陆进成   

  1. 210009 江苏省南京市,江苏省肿瘤医院,南京医科大学附属肿瘤医院胸外科(张治);化疗科(周国仁,方瑛);放疗科(叶劲军,顾大勇,李慧,陈薇,陈诚,钱普东,陶华,朱向帜,陆进成)
  • 收稿日期:2021-10-08 出版日期:2021-12-20 发布日期:2021-12-28
  • 通讯作者: 叶劲军,Email:jjye2004@163.com
  • 基金资助:
    江苏省青年医学人才项目(QNRC2016659,QNRC2016655);吴阶平医学基金会项目(320.6750.19194-60);江苏省“六大人才高峰”创新人才团队项目(TD-SWYY-007)

Efficacy of intensity modulated radiation therapy with concurrent chemotherapy of tegafur for the elderly patients with esophageal cancer: a phase Ⅱ clincal trial

ZHANG Zhi, ZHOU Guo-ren, YE Jin-jun, GU Da-yong, LI Hui, CHEN Wei, FANG Ying, CHEN Cheng, QIAN Pu-dong, TAO Hua, ZHU Xiang-zhi, LU Jin-cheng   

  1. ZHANG Zhi. Department of Thoracic Surgery; ZHOU Guo-ren, FANG Ying. Department of Chemotherapy;
    YE Jin-jun, GU Da-yong, LI Hui, CHEN Wei, CHEN Cheng, QIAN Pu-dong, TAO Hua, ZHU Xiang-zhi, LU Jin-cheng. Depart-ment of Radiotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing MedicalUniversity Affiliated Cancer Hospital, Nanjing 210009, China
  • Received:2021-10-08 Online:2021-12-20 Published:2021-12-28

PDF (PC)

970

摘要： 目的 探讨老年食管癌病人累及野放疗联合替吉奥治疗的安全性和疗效。 方法 共入组120例≥75岁食管鳞癌病人,采用累及野调强放射治疗(intensity modulated radiation therapy,IMRT)联合同期口服替吉奥治疗,观察主要总生存期(overall survival,OS)、无进展生存期(progression-free survival,PFS)以及不良反应的发生情况。 结果 病人的中位随访时间为41.2个月(5.9~90.4个月)。1、2、3年的总生存率为81.1%、64.8%、48.0%。1、2、3年的无进展生存率为77.6%、53.4%、39.3%。1、2、3年的肿瘤特异性总生存率为88.2%、78.5%、64.1%。3级以上不良反应均为血液学反应,包括3级血红蛋白下降1例(0.8%),3级白细胞下降9例(7.5%)、4级2例(1.7%),3级粒细胞下降3例(2.5%)、4级1例(0.8%),3级血小板下降4例(3.3%)。 结论 老年食管鳞癌病人行累及野放疗联合替吉奥同步化疗方案是安全有效的,不良反应是可耐受的,值得进一步开展Ⅲ期临床研究。

关键词: 食管癌, 调强放疗, 替吉奥

Abstract: Objective To evaluate the efficacy and toxic effects of intensity modulated radiation therapy(IMRT) combined with tegafur(S-1) in the elderly patients with esophageal cancer. Methods This was a single-arm, phase Ⅱ clinical study. A total of 120 elderly patients with esophageal squamous cell carcinoma aged ≥75 years old from May 2014 to April 2021 were recruited. The IMRT and chemotherapy were conducted. The adverse reactions and curative effects were observed. Results The median follow-up time was 41.2 months (5.9-90.4 months) by October 2021. One-, two- and three-year overall survival rate was 81.1%, 64.8%, and 48.0%, respectively. One-, two- and three-year progression-free survival rate was 77.6%, 53.4%, and 39.3%, respectively. One-, two- and three-year tumor specific overall survival rate was 88.2%, 78.5%, and 64.1%, respectively. The main toxic and side effects above grade 3 were hematological reactions, including grade 3 hemoglobin decreased in 1 case (0.8%), grade 3 leukocyte decreased in 9 cases (7.5%), grade 4 leukocyte decreased in 2 cases (1.7%), grade 3 granulocyte decreased in 3 cases (2.5%), grade 4 leukocyte decreased in 1 case (0.8%), and grade 3 platelet decreased in 4 cases (3.3%). Conclusions Involving field radiotherapy combined with concurrent chemotherapy with S-1 is safe and effective in the elderly patients with esophageal squamous cell carcinoma, and the toxic and side effects are tolerable. It is worthy of further phase Ⅲ clinical study.

Key words: esophageal cell carcinoma, intensity-modulated radiotherapy, tegafur

中图分类号: